LMR Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

LMR Partners’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,160	Closed	-$33.4K	–	1659
2026 Q1	$33.4K	Buy	+21,160	New	+$35.7K	﹤0.01%	1329
2023 Q2	–	Sell	-83,395	Closed	-$125K	–	1009
2023 Q1	$125K	Buy	+83,395	New	+$116K	﹤0.01%	914
2022 Q4	–	Sell	-44,733	Closed	-$51K	–	1195
2022 Q3	$51K	Hold	44,733	–	–	﹤0.01%	1097
2022 Q2	$71K	Buy	+44,733	New	+$59K	﹤0.01%	1125
2021 Q2	–	Sell	-72,194	Closed	-$170K	–	1233
2021 Q1	$170K	Buy	+72,194	New	+$173K	﹤0.01%	809
2020 Q4	–	Sell	-40,083	Closed	-$38K	–	564
2020 Q3	$38K	Sell	40,083 -7,074	-15%	-$6.25K	﹤0.01%	400
2020 Q2	$41K	Buy	+47,157	New	+$41.5K	﹤0.01%	537
2015 Q2	–	Sell	-22,658	Closed	-$91K	–	576
2015 Q1	$91K	Buy	+22,658	New	+$78.4K	0.01%	375

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LMR Partners's LCTX Position: Q2 2026 in Review

LMR Partners sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 21,160 shares — an estimated $33.4K sold.

LMR Partners first reported a position in LCTX in Q1 2015 and held it in 8 quarters. The position peaked at $170K in Q1 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

LMR Partners reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 21,160 Lineage Cell Therapeutics shares in Q2 2026, an estimated $33.4K.
LMR Partners first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 8 quarters.
LMR Partners's Lineage Cell Therapeutics position peaked at $170K in Q1 2021.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.